Latest news with #IanGriffiths
Vogue
2 days ago
- Entertainment
- Vogue
Balmain Resort 2026 Menswear Collection
Olivier Rousteing is still under 40. Yet he is also the third longest-standing non-founder creative director in ready-to-wear luxury fashion (after evergreen Véronique Nichanian at Hermès menswear and the mighty Ian Griffiths of Max Mara). So even as fashion cycles through its latest red wedding moment, Rousteing's combination of veteran experience and youthful potential allows him to take a pragmatic and sanguine view. Speaking in his office, he said: 'A designer needs to change: to develop through reinvention. So it's not just only a house becoming bored of a designer and looking to change—the designer him or herself should become bored if they do not change how and what they do. You keep your DNA, but you make very different albums.' At Balmain, Rousteing remains both signed to the label and committed to perpetual reinvention. The photography of these resort lookbooks reflected his intention to approach the collection from a fresh angle while deploying his deep expertise in the business to maximize its performance. In womenswear, a focus on bouclé pieces in pastel checks (a little Clueless), black, and some racier color-combos kept aside in the showroom reflected the fact that around over 20% of Balmain's ready-to-wear pieces are in tweed. A seasonal floral reworked from a Pierre Balmain original was present in some of the multiple new fabrications of a growing core line of Balmain handbags; the Anthem (belt buckle), the Sync (chain), the Ébène (par-baked croissant), and the tightly-waisted Shuffle. Knit bandage dresses and a split skirt floral aside, there was a notable step away from bodycon towards a focus on innovatively detailed oversized tailoring in wools including prince of wales check that often came cropped and placed in silhouette-skewing adjacency to matching microskirts and shorts. A coat so roomy you could put it on Airbnb came patterned with a felted Monet-esque print that reflected Pierre Balmain's artistic passions, Rousteing reported. His column-pediment wedge boots were delivered this season in a shearling fabrication as well as leathers and worn against lingerie dresses. Cocoon-like capes in peach or lemon cashmere were standout wardrobe pieces. Menswear played a radical-conservative gambit of contrasting extreme tailoring—either angular and fitted, or oversized and softer—against denim, leather, or jacquard sportswear. Formal shoes were elevated from banaility by raised soles and extruded metal welting. You could see both bourgeois French paradigms and street silhouettes transposed to tailored fabrications. Lurking in the showroom were many non-shot but still highly photogenic pieces, including labyrinth pattern shirt-and-short sets, leather and wool stadium jacket blouson hybrids, and bouclé overshirts. Said Rousteing: 'The real question is always what do you want to propose? And while my answer changes through the seasons, it also always relates to going back to the past and bringing it to the present in order to build the future. This is why I am always having this conversation with the original work of Pierre Balmain, and looking to express that dialogue in new ways.'
Yahoo
4 days ago
- Business
- Yahoo
Angle PLC Announces Posting of Annual Report and Notice of AGM
GUILDFORD, SURREY / / June 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financial Statements for the year ended 31 December 2024, and the Notice of Annual General Meeting ("AGM") within it, have been posted to shareholders, and are available on the Company's website. The AGM will be held at 2:00 pm on Monday 30 June 2025 at the Surrey Technology Centre, Surrey Research Park, Guildford, Surrey GU2 7YG. The Board is looking forward to welcoming shareholders in person and will provide a business update after the formalities of the meeting are concluded. For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product: The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: ANGLE plc View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Angle PLC Announces Posting of Annual Report and Notice of AGM
GUILDFORD, SURREY / / June 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financial Statements for the year ended 31 December 2024, and the Notice of Annual General Meeting ("AGM") within it, have been posted to shareholders, and are available on the Company's website. The AGM will be held at 2:00 pm on Monday 30 June 2025 at the Surrey Technology Centre, Surrey Research Park, Guildford, Surrey GU2 7YG. The Board is looking forward to welcoming shareholders in person and will provide a business update after the formalities of the meeting are concluded. For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product: The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: ANGLE plc View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-05-2025
- Business
- Yahoo
ANGLE PLC (ANPCY) (Q4 2024) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Revenue Growth: 31% increase in 2024 compared to 2023. Gross Margin: Maintained at approximately 62%. Operating Expenditure: Reduced by 21%. Net Loss Reduction: Decreased by 29%. Cash Runway: GBP11.6 million, lasting into Q1 2026. Fundraising: Raised GBP9.3 million gross in June 2024. Pharma Contracts: Secured three large pharma contracts and one large biopharma contract. Potential Revenue from Trials: GBP1 million to GBP4 million for Phase 2 trials; GBP15 million to GBP45 million for Phase 3 trials. Companion Diagnostic Revenue Potential: Estimated at GBP20 million annually per program. Warning! GuruFocus has detected 2 Warning Signs with ANPCY. Release Date: May 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. ANGLE PLC (ANPCY) achieved a 31% growth in revenues for 2024 compared to 2023, despite adverse market conditions. The company successfully secured three large pharma contracts and one large biopharma contract, with all progressing well and concluding successfully. ANGLE PLC (ANPCY) developed a new DNA dual analysis method, offering unique insights by analyzing both living cancer cells and fragments of dead cells. The company reduced operating expenditure by 21%, contributing to a 29% reduction in losses. ANGLE PLC (ANPCY) has over 100 peer-reviewed publications from independent cancer centers validating the effectiveness of its Parsortix system. There are delays in decision-making from large pharma companies, affecting the timing of potential contracts. The company faces challenges due to the tightening funding environment, impacting smaller biopharma companies and delaying some projects. Uncertainty in research funding, particularly in the US, is causing delays in purchasing decisions from research institutions. The company is experiencing delays in the procurement process in Europe, even when they are the preferred vendor. ANGLE PLC (ANPCY) faces competition from established methods like circulating tumor DNA (CT-DNA) analysis, requiring significant market education efforts. Q: Can you give us a sense of how discussions with potential medtech partners are going and the size of the opportunity compared to pharma? A: Andrew Newland, Chief Executive, explained that while pharma has a defined process for clinical trials, medtech opportunities, though fewer, can be substantial. Medtech companies are interested in using Parsortix for repeat testing, which could significantly expand their revenue opportunities. The cost of tissue biopsy in metastatic breast cancer is high, and Parsortix offers a cheaper alternative. Q: Have you seen evidence of project cancellations or delays affecting the business? A: Ian Griffiths, Chief Financial Officer, noted that there have been some delays, such as Eisai handing back a project to BlissBio. This creates uncertainty, but discussions with BlissBio are ongoing. The pipeline is building, but decision-making has been slower due to market conditions. Q: Does your cash runway through Q1 2026 assume further cost reductions? A: Ian Griffiths stated that while they continue to manage costs, investments in the clinical lab are necessary to meet the requirements of large clients like AstraZeneca. They aim to keep the cost base tight while ensuring they have the capacity to deliver. Q: Is there a Parsortix product development pipeline, and what does it look like? A: Andrew Newland mentioned that the focus is on developing uses for cancer cells rather than the instrumentation itself. The Parsortix system is stable, and development work is centered on methods to analyze cancer cells, funded mainly by customers. Q: Are large pharma opportunities more about educating them on CTC technology or competition with CT-DNA? A: Andrew Newland explained that educating pharma about CTCs is crucial. Some may not be familiar with CTCs or have had past experiences with older systems. Demonstrating the advantages of Parsortix and providing data is key to gaining their interest. Q: How are tariffs affecting your business? A: Ian Griffiths noted that tariffs in the US are passed directly to customers, as Angle has a unique offering that cannot absorb these costs. Customers accept this as part of dealing with Angle. Q: Do you have visibility on when funding for basic research might open up again? A: Ian Griffiths stated that there is uncertainty due to potential budget cuts in the US. Some institutions may secure funds from other sources, but government institutions might struggle, affecting their ability to fund projects. Q: Do you have visibility on when large pharma like AstraZeneca will make decisions? A: Ian Griffiths acknowledged the challenge in predicting timing. While the pipeline is strong, uncertainty in the environment means they must be cautious in their expectations. Revenue recognition will also be spread over time once deals are signed. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
The Independent
27-02-2025
- Entertainment
- The Independent
Max Mara offers cashmere comfort when the day, or the world, goes awry
The Max Mara woman is following her dreams and taking comfort in well-tailored cashmere in soothing monochromes when the day — or world — goes awry. The silhouette of new collection for next fall and winter premiering during Milan Fashion Week on Thursday featured a fitted bodice flowing into big skirts and wide-legged trousers that cinched tightly at the waist. Knitwear was ribbed, anchored by provocatively thigh-high tights. Outerwear was fluid without being oversized; double belts accentuated the form. Shawl collars could be pulled up into protective hoods. Max Mara hewed to its traditional monochromes: burgundy, black, camel and a creamy color that the brand calls cascia, for the natural color of cashmere. Creative director Ian Griffiths said the well-tailored looks with shearling or quilted layers could be worn 'to march through the moors of Yorkshire, or sleep under a bush. Although of course, this woman is more likely to be marching through the corridors of power.' 'It's the moment where this woman who has been applying herself through cold logic to climbing the corporate ladder all these years has been denying herself this inner passion, and with the world as it is, she just has to find expression for it,'' Griffiths said.
